Paracetamol 500 mg Film-Coated Tablets (p)

  • Name:

    Paracetamol 500 mg Film-Coated Tablets (p)

  • Company:
    info
  • Active Ingredients:

    Paracetamol

  • Legal Category:

    Supply through pharmacy only

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 23/10/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 23/10/2019

Click on this link to Download PDF directly

Chefaro Ireland Ltd

Chefaro Ireland Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Abidec Drops Active Ingredients Ascorbic acid, nicotinamide (B3), Pyridoxine Hydrochloride (Vitamin B6), Riboflavine (Vitamin B2), Thiamine Hydrochloride (Vitamin B1), Vitamin A (Palmitate), Vitamin D2 (ergocalciferol)
Medicine Name Beconase Hayfever Active Ingredients Beclometasone Dipropionate Monohydrate
Medicine Name Buttercup Bronchostop Berry Flavour Cough Pastilles Active Ingredients Thyme herb extract
Medicine Name Buttercup Bronchostop Cough Syrup Active Ingredients Marshmallow root extract, Thyme herb extract
Medicine Name Cetirizine dihydrochloride 10mg Film-coated Tablets Active Ingredients Cetirizine Dihydrochloride
Medicine Name Lyclear Creme Rinse Active Ingredients Permethrin
Medicine Name Metatone Tonic Active Ingredients Calcium glycerophosphate, Manganese glycerophosphate, Potassium glycerophosphate, Sodium glycerophosphate, Thiamine Hydrochloride (Vitamin B1)
Medicine Name Milk of Magnesia Active Ingredients Magnesium Hydroxide
Medicine Name NiQuitin 14 mg/24hrs transdermal patches Active Ingredients Nicotine
Medicine Name NiQuitin 21mg/24hrs transdermal patches Active Ingredients Nicotine
Medicine Name NiQuitin 7mg/24hrs transdermal patches Active Ingredients Nicotine
Medicine Name NiQuitin CLEAR 14 mg/24 hours transdermal patch Active Ingredients Nicotine
Medicine Name NiQuitin CLEAR 21 mg/24 hours transdermal patch Active Ingredients Nicotine
Medicine Name NiQuitin CLEAR 7 mg/24 hours transdermal patch Active Ingredients Nicotine
Medicine Name NiQuitin CLEAR transdermal patch Active Ingredients Nicotine
Medicine Name NiQuitin Mini 1.5mg mint lozenges Active Ingredients Nicotine resinate
Medicine Name NiQuitin Mini 4mg mint lozenges Active Ingredients Nicotine resinate
Medicine Name Paracetamol 500 mg Film-Coated Tablets (GSL) Active Ingredients Paracetamol
Medicine Name Paracetamol 500 mg Film-Coated Tablets (p) Active Ingredients Paracetamol
Medicine Name PrevAllergy Tablets Active Ingredients Cetirizine Dihydrochloride
Medicine Name Solpa-Extra Soluble Tablets Active Ingredients Caffeine, Paracetamol
Medicine Name Solpa-Plus tablets Active Ingredients Codeine Phosphate Hemihydrate, Paracetamol
Medicine Name solpa-plus with caffeine soluble tablets Active Ingredients Caffeine, Codeine Phosphate Hemihydrate, Paracetamol
Medicine Name Solpa-Sinus Film-coated Tablets Active Ingredients Paracetamol, Pseudoephedrine Hydrochloride
Medicine Name Solpadeine Capsules Active Ingredients Caffeine, Codeine Phosphate Hemihydrate, Paracetamol
1 - 0 of 33 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 23 October 2019 PIL

Reasons for updating

  • Change to section 6 - date of revision
  • Change to MA holder contact details

Free text change information supplied by the pharmaceutical company

Changee of MAH address

Updated on 23 October 2019 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change to MA holder contact details

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Change of MAH address

Updated on 24 August 2018 PIL

Reasons for updating

  • Change to product name

Updated on 24 August 2018 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product

Legal category: Supply through pharmacy only

Updated on 20 February 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Supply through pharmacy only

Updated on 20 February 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Pediatric posology change - MHRA led  

Updated on 17 November 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 17 November 2017 PIL

Reasons for updating

  • Change to section 3 - how to take/use
  • Change to section 6 - date of revision

Updated on 4 October 2017 PIL

Reasons for updating

  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 30 August 2017 SmPC

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text
  • Maize starch
  • Potassium sorbate
  • Talc
  • Stearic acid
  • Povidone
  • Pre-gelatinised starch
  • Hypromellose
  • Triacetin
  • Brilliant Blue (E133)
  • Silicone antifoam emulsion
  • shellac
  • sodium lactate

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

3 Pharmaceutical Form


Film-coated
tablet

White film coated capsule-shaped tablet with flat edges marked 'Hedex' on both sides and a break line on one side. The break line is only to facilitate breaking for ease of swallowing only and do not divide into equal doses.



6.1 List of excipients

  • Maize starch
  • Potassium sorbate
  • Talc
  • Stearic acid
  • Povidone
  • Pre-gelatinised starch
  • Hypromellose
  • Triacetin
  • Brilliant Blue (E133)
  • Silicone antifoam emulsion
  • shellac
  • sodium lactate

10 Date of Revision of the text
April- August 2017

Updated on 16 June 2017 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Updated revision of text date

Updated on 31 May 2017 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Update to the MAH address (section 7) to:
Chefaro
Ireland DAC, Treasury Building

Lower Grand Canal Street Dublin 2,

Ireland

Updated on 26 May 2017 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 19 November 2015 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

4.1  Posology and method of administration

 

Oral administration only.

Adults (including the elderly):

2 tablets repeated if necessary 3-4 times a day to a maximum of 8 tablets in any 24 hour period.

Paediatric population

Children 6-12 years:

The usual dose is 1 tablet repeated if necessary 3-4 times a day to maximum of 4 tablets in any 24 hour period. Hedex tablets are not suitable for children under 6 years of age.

These doses should not be repeated more frequently than every 4 hours and not more than 4 doses should be given in any 24 hour period.

 

Maximum duration of continued use without medical advice: 3 days.

 

 

4.2  Contraindications

 

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Use in children under 6 years of age.

 

4.3  Special warnings and precautions for use

 

Hepatic impairment

Underlying liver disease increases the risk of paracetamol-related liver damage. Patients with renal or hepatic impairment should seek medical advice prior to treatment with paracetamol. The hazard of overdose is greater in those with non-cirrhotic alcoholic liver disease.

 

Do not exceed the stated dose.

 

Patients should be advised not to take other paracetamol-containing products concurrently. If symptoms persist, consult your doctor.

 

Keep out of the sight and reach of children.

 

Consult your doctor if you are taking warfarin or have been diagnosed with liver or kidney disease.

 

4.4   Interaction with other medicinal products and other forms of interaction

 

The speed of absorption of paracetamol may be increased by metoclopramide or domperidone.  The rate of paracetemol absorption may be reduced by colestyramine. Colestyramine should not be administered within one hour of taking paracetamol. 

 

The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular daily use of paracetamol with increased risk of bleeding; occasional doses have no significant effect.

 

In case of concomitant treatment with probenecid, the dose of paracetemol should be reduced because the probenecid reduces the clearance of paracetemol by 50% because it prevents the conjugation of paracetamol with glucuronic acid.

 

There is limited evidence to suggesting that paracetamol may affect cholaramphenicol pharmacokinetics but its validity has been criticised and evidence of a clinically relevant interaction appears to lack. Although no routine monitoring needed, it is important to bear in mind this potential interaction when these two medications are concomitantly administered, especially in malnourished patients.

 

 

4.5  Fertility, pregnancy and lactation

 

Pregnancy

Epidemiological studies in human pregnancy have shown no ill effects due to paracetamol used in the recommended dosage, but patients should follow the advice of their doctor regarding its use.

 

Breast-feeding

Paracetamol is excreted in breast milk but not in a clinically significant amount. Available published data do not contraindicate breast feeding.

 

Fertility

There are no available data on the effect of paracetamol on fertility.

 

4.6  Effects on ability to drive and use machines

 

Hedex has no or negligible influence on the ability to drive and use machines.

 

4.7  Undesirable effects

 

Adverse events associated with paracetamol from historical clinical trial data are both infrequent and from small patient exposure. Accordingly, events reported from extensive post-marketing experience at therapeutic/labeled dose and considered attributable are tabulated below by System Organ Class and frequency. Frequencies are defined as: very common (>1/10), common (>1/100, <1/10), uncommon (>1/1000, <1/100), rare (>1/10,000, <1/1000) and very rare (<1/10,000),  not known (cannot be estimated from the available data).

 

Immune system disorders

Allergies (not including angioedema)

Rare

Skin and subcutaneous tissue disorders

Cutaneous hypersensitivity reactions, including skin rashes, pruritus, sweating, purpura, urticaria and angioedema.

Very rare

TOXIC EPIDERMAL NECROLYSIS (TEN), DRUG-INDUCED DERMATITIS, Stevens Johnson syndrome. Anaphylaxis.

Very rare

Haematological system disorders

 

Thrombocytopaenia

Very rare

Respiratory system disorders

Aggravation of bronchospasm has been reported in asthmatic patients known to be sensitive to aspirin and other non-steroidal anti-inflammatory drugs

Very rare

Hepatobiliary disorders

Liver dysfunction

Very rare

Renal and urinary disorders

Sterile pyuria (cloudy urine)

Very rare

 

 

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

 

 

4.8  Overdose

 

Symptoms of paracetamol overdose in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In sever poisoning, hepatic failure may progress to encephalopathy, coma and death. Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. Liver damage is possible in adults who have taken 10g or more of paracetamol. It is considered that excess quantities of a toxic metabolite (usually adequately detoxified by glutathione when normal doses of paracetamol are ingested), become irreversibly bound to liver tissue.

 

Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention and any patient who has ingested around 7.5g or more of paracetamol in the preceding 4 hours should undergo gastric lavage. Administration of oral methionine or intravenous N-acetylcysteine which may have a beneficial effect up to at least 48 hours after the overdose, may be required.

General supportive measures must be available.

 

Risk factors:

 

If the patient

a) is on long term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St. John’s Wort or other drugs that induce liver enzymes

or

b) regularly consumes ethanol in excess of recommended amounts

or

c) is likely to be glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia

4.1  Special precautions for disposal

 

No special requirements.


10 DATE OF REVISION OF THE TEXT

 

November 2015


Updated on 18 November 2015 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 20 August 2013 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - MA number
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 7 MAH holder address changed from GSK Ireland to below:

Chefaro Ireland Limited First Floor

Block A

The Crescent Building Northwood Office Park

Dublin 9 Ireland

Section 8 Marketing authoriastion number changed to PA 1186/009/001

 


Section 10 Revisions date changed to January 2013

Updated on 6 February 2013 PIL

Reasons for updating

  • Change to date of revision
  • Change to marketing authorisation holder

Updated on 6 August 2010 PIL

Reasons for updating

  • Change of contraindications
  • Transfer of Marketing Authorisation Holder
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to date of revision
  • Change to improve clarity and readability
  • Change of special precautions for disposal
  • Change due to user-testing of patient information
  • Introduction of new pack/pack size

Updated on 28 January 2010 SmPC

Reasons for updating

  • Transfer of marketing authorisation holder
  • Change to section 4.2 - Posology and method of administration
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 4.2

the following sentence is added:

Maximum duration of continued use without medical advice: 3 days.

Updated on 9 September 2009 SmPC

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 3-Update of tablet description
Section 6.1-Addition of printing ink ingredients
Section 10-Updated date of revision

Updated on 11 December 2008 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 4.4                 

Caution is advised in the administration of paracetamol to patients with severe renal or severe hepatic impairment. Underlying liver disease increases the risk of paracetamol-related liver damage. Patients with renal or hepatic impairment should seek medical advice prior to treatment with paracetamol. The hazard of overdose is greater in those with non-cirrhotic alcoholic liver disease.

 

Do not exceed the stated dose.

 

Patients should be advised not to take other paracetamol-containing products concurrently.

 

If symptoms persist consult your doctor.

 

Keep out of the reach and sight of children.

 

Consult your doctor if you are taking warfarin or have been diagnosed with liver or kidney disease.

 

 

Section 4.8

 

Adverse effects of paracetamol are rare but hypersensitivity including skin rash may occur.

Adverse events associated with paracetamol from historical clinical trial data are both infrequent and from small patient exposure. Accordingly, events reported from extensive post-marketing experience at therapeutic/labeled dose and considered attributable are tabulated below by System Organ Class and frequency.  Frequencies are defined as: very common (>1/10), common (>1/100, <1/10), uncommon (>1/1000, <1/100), rare (>1/10,000, <1/1000) and very rare (<1/10,000) including isolated reports.

Immune system disorders

Very rare (< 1/10,000) Cutaneous hypersensitivity reactions, including skin rashes, angioedema and Stevens Johnson syndrome. Anaphylaxis.

Haematological system disorders

Very rare (<1/10,000) thrombocytopaenia

Respiratory system disorders

Very rare (<1/10,000) aggravation of bronchospasm has been reported in asthmatic patients known to be sensitive to aspirin and other non-steroidal anti-inflammatory drugs

Hepatobiliary disorders

Very rare (<1/10,000) Liver dysfunction

 

 

Section 5.1

ATC Code :  N02BE01

 

Paracetamol is an analgesic and antipyretic.  Its mechanism of action is believed to include inhibition of prostaglandin synthesis, primarily within the central nervous system

 

Updated on 20 November 2008 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 20 November 2008 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.5 - Nature and contents of container
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 1:         Hedex 500mg Film-coated Tablets

 

Section 2:         Each tablet contains paracetamol 500mg.

                       

                         For a full list of excipients, see section 6.1.

 

Section 6.5:      Opaque PVC/aluminium foil blister strips packed into cardboard boxes                         containing 12, 16, 24 or 40 tablets.

 

                        Not all pack sizes may be marketed.

 

Section 9:         Date of last renewal: 20 August 2007

 

Section 10:       November 2008

Updated on 27 August 2008 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Supply through pharmacy only

Updated on 20 August 2008 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 19 August 2008 SmPC

Reasons for updating

  • Improved electronic presentation
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 3 The first sentence was changed to say "Film-coated tablet".

 

Section 4.9 Changed to the following:

Symptoms of paracetamol overdose in the first 24 hours are pallor, nausea, vomiting, anorexia, and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, coma and death. Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. Liver damage is possible in adults who have taken 10g or more of paracetamol. It is considered that excess quantities of a toxic metabolite (usually adequately detoxified by glutathione when normal doses of paracetamol are ingested), become irreversibly bound to liver tissue.

Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention and any patient who has ingested around 7.5g or more of paracetamol in the preceding 4 hours should undergo gastric lavage. Administration of oral methionine or intravenous N-acetylcysteine which may have a beneficial effect up to at least 48 hours after the overdose, may be required.      General supportive measures must be available.

 

 

Section 10 the date of revision of the text was changed to say January 2005.

 

Updated on 27 August 2007 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 6 July 2005 PIL

Reasons for updating

  • Change of active ingredient

Updated on 12 May 2005 SmPC

Reasons for updating

  • Change to section 6.1 - List of excipients

Legal category: Supply through pharmacy only

Updated on 24 September 2004 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 9 August 2004 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Updated on 30 July 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Supply through pharmacy only